Health Insurance Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Hospital Fribourg

Recent findings from Switzerland, the United States and France illuminate research in lung cancer

Study 1: Docetaxel-cisplatin was found to be effective and tolerable in patients with stage IIIA pN2 non-small-cell lung cancer (NSCLC).

"The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) NSCLC patients. In all, 75 patients (from 90 enrolled) underwent tumor resection after three 3-week cycles of docetaxel 85 mg/m² (day 1) plus cisplatin 40 or 50 mg/m² (days 1 and 2)," scientists in Switzerland reported.

...

• View Other Issues of Health Insurance Law Weekly
  
• View Other NewsRx Publications